<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879110</url>
  </required_header>
  <id_info>
    <org_study_id>ASD201512</org_study_id>
    <nct_id>NCT02879110</nct_id>
  </id_info>
  <brief_title>A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder</brief_title>
  <official_title>A 12-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Related Mechanism of Sulforaphane in Treatment of Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Davis family funding</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proposed study, the investigators will evaluate the the efficacy, safety and related
      mechanism of sulforaphane in treatment of autism spectrum disorder (ASD). The study will
      recruit 120 ASD patients, then these patients will be randomized to sulforaphane group or
      placebo group (60 patients per arm) for 12 weeks clinic trial. Clinical efficacy and safety
      assessment will be done at screen/baseline, 4 week, 8 week and 12 week. The specific aims are
      to compare sulforaphane versus placebo on: 1) clinical core symptoms; 2) other behavioral
      problems and adaptive behaviors. Biological samples also will be collected, and stored to
      research related mechanisms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this proposed study, the investigators will evaluate the the efficacy, safety and related
      mechanism of sulforaphane in treatment of autism spectrum disorder (ASD). The study will
      recruit 120 ASD patients, then these patients will be randomized to sulforaphane group or
      placebo group (60 patients per arm) for 12 weeks clinic trial. Clinical efficacy and safety
      assessment will be done at screen/baseline, 4 week, 8 week and 12 week. The specific aims are
      to compare sulforaphane versus placebo on: 1) clinical core symptoms; 2) other behavioral
      problems and adaptive behaviors. The investigators hypothesize that (1) sulforaphane is
      superior to placebo in the treatment of clinical symptoms in patients with ASD, measured by
      the Social Responsiveness Scale, Aberrant Behavior Checklist, Repetitive Behavior Scale -
      Revised and Ohio State University Autism Clinical Global Impression; (2) sulforaphane is
      superior to placebo in the treatment of other behavioral problems and adaptive behaviors
      patients with ASD, measured by Achenbach's Child Behavior Checklist and Adaptive Behavior
      Assessment System, Second Edition; and (3) Biological samples will be collected, and stored
      so that the hypothesis sulforaphane may alter oxidative stress indexes or inflammatory
      biomarkers, and influence histone deacetylase inhibitor mechanism or inflammatory mechanism
      et al that may be significantly correlated with clinical improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of social impairments of children with autism spectrum disorder</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Social impairments are measured by Social Responsiveness Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of rigid interests and behaviors of children with autism spectrum disorder</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Rigid interests and behaviors are measured by Repetitive Behavior Scale - Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of clinical symptoms of children with autism spectrum</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Clinical symptoms are measured by Aberrant Behavior Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of other behavioral problems of children with autism spectrum</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Other behavioral problems are measured by Achenbach's Child Behavior Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of adaptive behaviors of children with autism spectrum</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Adaptive behaviors are measured by Adaptive Behavior Assessment System, Second Edition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of clinical general impression of children with autism spectrum</measure>
    <time_frame>At baseline, 4 week, 8 week and 12 week/endpoint</time_frame>
    <description>Clinical general impression is measured by Ohio State University Autism Clinical Global Impression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of heart rate as measured by stopwatch</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of weight as measured by weighing-machine</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of height as measured by Height measurement tools</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of blood routine test as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of fasting blood-glucose as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of blood lipid as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of liver function as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of kidney function as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of thyroid function as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HBV test as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of helicobacter pylori test as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of urine routine test as tested by clinical laboratory</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by Systematic Assessment for Treatment Emergent Effects</measure>
    <time_frame>At 4 week, 8 week and 12 week/endpoint</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change of Oxidative stress indexes as tested by Oxidative stress indexes detection kit</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change of Epigenetics indicators as tested by Epigenetics indicators</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change of Cytokines &amp; Chemokines as tested by Cytokines &amp; Chemokines detection kit</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change of Metabolites as tested by Metabolites detection kit</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change of RNA expression as tested by RNA expression detection kit</measure>
    <time_frame>At baseline and 12 week/endpoint</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Sulforaphane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will take sulforaphane for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will take placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sulforaphane</intervention_name>
    <description>Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.</description>
    <arm_group_label>Sulforaphane group</arm_group_label>
    <other_name>85313323</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet is composed of starch.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Starch tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male with aged 10 to 15 years.

          2. Meet DSM-V diagnostic criteria for autism spectrum disorder, and been checked with
             Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule
             (ADOS).

        Exclusion Criteria:

          1. With severe physical disease (i.e. congenital heart disease, thyroid disease, diseases
             with severe abnormality of liver or kidney function, diseases with abnormality vision
             or hearing et al.)

          2. With severe central nervous system disease (i.e. epilepsy et al).

          3. With other specific genetic syndromes (i.e. Fragile-X syndrome, Down's syndrome et
             al.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingping Zhao, M.D., Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianjun Ou, M.D., Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Jin, M.D., Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Psychiatry, University of California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengyu Zhang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Clinical and Translational Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daomeng Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Huiai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renrong Wu, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M Davis, M.D.,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Department of Psychiatry, University of Illinoisat at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Ou, M.D., Ph. D.</last_name>
    <phone>86-18684971485</phone>
    <email>oujianjun08@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingping Zhao, M.D., Ph. D.</last_name>
    <phone>86-13808465728</phone>
    <email>zhaojingpingcsu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou Huiai Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daomeng Cheng, M.D.</last_name>
      <email>4336032@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second Xiangya hospital of central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Ou, M.D., Ph.D</last_name>
      <phone>86-18694971485</phone>
      <email>oujianjun08@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanan Liu, Master</last_name>
      <phone>86-18008422158</phone>
      <email>610122024@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yidong Shen, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yamin Li, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanan Liu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lijuan Shi, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xilong Cui, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Liu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Qiu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lu Xiao, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Foley AG, Cassidy AW, Regan CM. Pentyl-4-yn-VPA, a histone deacetylase inhibitor, ameliorates deficits in social behavior and cognition in a rodent model of autism spectrum disorders. Eur J Pharmacol. 2014 Mar 15;727:80-6. doi: 10.1016/j.ejphar.2014.01.050. Epub 2014 Jan 31.</citation>
    <PMID>24486700</PMID>
  </reference>
  <reference>
    <citation>Houghton CA, Fassett RG, Coombes JS. Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev. 2013 Nov;71(11):709-26. doi: 10.1111/nure.12060. Epub 2013 Oct 22. Review.</citation>
    <PMID>24147970</PMID>
  </reference>
  <reference>
    <citation>Moldrich RX, Leanage G, She D, Dolan-Evans E, Nelson M, Reza N, Reutens DC. Inhibition of histone deacetylase in utero causes sociability deficits in postnatal mice. Behav Brain Res. 2013 Nov 15;257:253-64. doi: 10.1016/j.bbr.2013.09.049. Epub 2013 Oct 5.</citation>
    <PMID>24103642</PMID>
  </reference>
  <reference>
    <citation>Foley AG, Gannon S, Rombach-Mullan N, Prendergast A, Barry C, Cassidy AW, Regan CM. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder. Neuropharmacology. 2012 Sep;63(4):750-60. doi: 10.1016/j.neuropharm.2012.05.042. Epub 2012 Jun 6.</citation>
    <PMID>22683514</PMID>
  </reference>
  <reference>
    <citation>Montes G, Halterman JS. Association of childhood autism spectrum disorders and loss of family income. Pediatrics. 2008 Apr;121(4):e821-6. doi: 10.1542/peds.2007-1594.</citation>
    <PMID>18381511</PMID>
  </reference>
  <reference>
    <citation>Montes G, Halterman JS. Child care problems and employment among families with preschool-aged children with autism in the United States. Pediatrics. 2008 Jul;122(1):e202-8. doi: 10.1542/peds.2007-3037.</citation>
    <PMID>18595965</PMID>
  </reference>
  <reference>
    <citation>Mugno D, Ruta L, D'Arrigo VG, Mazzone L. Impairment of quality of life in parents of children and adolescents with pervasive developmental disorder. Health Qual Life Outcomes. 2007 Apr 27;5:22.</citation>
    <PMID>17466072</PMID>
  </reference>
  <reference>
    <citation>Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood). 2007 Feb;232(2):227-34.</citation>
    <PMID>17259330</PMID>
  </reference>
  <reference>
    <citation>Ou JJ, Shi LJ, Xun GL, Chen C, Wu RR, Luo XR, Zhang FY, Zhao JP. Employment and financial burden of families with preschool children diagnosed with autism spectrum disorders in urban China: results from a descriptive study. BMC Psychiatry. 2015 Jan 22;15:3. doi: 10.1186/s12888-015-0382-4.</citation>
    <PMID>25608486</PMID>
  </reference>
  <reference>
    <citation>Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012 Apr;17(4):389-401. doi: 10.1038/mp.2011.165. Epub 2011 Dec 6. Review.</citation>
    <PMID>22143005</PMID>
  </reference>
  <reference>
    <citation>Schieve LA, Blumberg SJ, Rice C, Visser SN, Boyle C. The relationship between autism and parenting stress. Pediatrics. 2007 Feb;119 Suppl 1:S114-21.</citation>
    <PMID>17272578</PMID>
  </reference>
  <reference>
    <citation>Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, Zimmerman AW. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15550-5. doi: 10.1073/pnas.1416940111. Epub 2014 Oct 13.</citation>
    <PMID>25313065</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Jian-Jun Ou</investigator_full_name>
    <investigator_title>Assistant researcher</investigator_title>
  </responsible_party>
  <keyword>Sulforaphane</keyword>
  <keyword>clinic trial</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Mechanism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

